In subgroup analyses, lower risk was seen with cumulative dosage of ≥401 mg or with therapy duration of five years or longer

At three, six, and nine years, overall survival was 64, 43, and 26 percent and progression-free survival was 88, 78, and 78 percent, respectively

Eight of nine patients with major pathological response (MPR) were alive and disease-free at five years, while six of 11 without MPR experienced relapse

Improvement observed in detection of actionable lung nodules with no increase in false-referral rates

Sublobar resection is noninferior for disease-free and overall survival for patients with tumors ≤2 cm

Risk model-based lung cancer screening strategy more cost-effective than 2021 USPSTF recommendations

Despite NCCN guidelines recommending FDG PET/CT, 43.6 percent of patients were imaged with CT alone before subsequent radiation therapy

Sybil achieved areas under receiver operating characteristic curve of 0.92, 0.86, and 0.94 on three external validation sets

Shape-sensing robotic-assisted bronchoscopy with imaging has high diagnostic accuracy, sensitivity, specificity

Based on inverse variance weighted method, GERD found to substantially increase lung cancer risk